BR112013018744A2 - método para produzir um polipetídeo ou uma proteína recombinante - Google Patents

método para produzir um polipetídeo ou uma proteína recombinante

Info

Publication number
BR112013018744A2
BR112013018744A2 BR112013018744A BR112013018744A BR112013018744A2 BR 112013018744 A2 BR112013018744 A2 BR 112013018744A2 BR 112013018744 A BR112013018744 A BR 112013018744A BR 112013018744 A BR112013018744 A BR 112013018744A BR 112013018744 A2 BR112013018744 A2 BR 112013018744A2
Authority
BR
Brazil
Prior art keywords
treat
redifferentiated
animal
nucleic acid
producing
Prior art date
Application number
BR112013018744A
Other languages
English (en)
Other versions
BR112013018744B1 (pt
Inventor
Thereza D Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of BR112013018744A2 publication Critical patent/BR112013018744A2/pt
Publication of BR112013018744B1 publication Critical patent/BR112013018744B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

método para produzir um polipetídeo ou uma proteína recombinante a invenção fornece um método para produzir produtos de poliptídeo ou proteína e produtos de ácido nucléico níveis reduzidos de antigenicidade em um animal que está sendo tratado com um produto biológico. célula somáticas são isoladas de um animal, transformadas em células tronco pluripotentes, transfectadas com ácido (s) nucléico (s) de interesse, e rediferenciadas rumo a células somáticas conhecidas como tendo elevado nível de produtores do produto de ácido nucléico desejado. a invenção pode ser usada para derivar uma linhagem de células genéricas para tratar populações, linhagens de células específicas raciais para tratar grupos étnicos, ou linhagens de células específicas do paciente para tratar indivíduos. além disso, a invenção fornece um método que permite que células tronco pluripotentes induzidas sejam rediferenciadas rumo à sua célula tronco pluripotentes induzidas sejam rediferenciadas rumo à sua célula somática de origem, de tal forma que as células possam ser usadas para tratar terapeuticamente um animal sem resultar na formação de teratoma.
BR112013018744-1A 2011-01-03 2012-01-03 Método para produzir um polipetídeo ou uma proteína recombinante BR112013018744B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161429409P 2011-01-03 2011-01-03
US61/429,409 2011-01-03
US201161431376P 2011-01-10 2011-01-10
US61/431,376 2011-01-10
PCT/US2012/020084 WO2012094321A1 (en) 2011-01-03 2012-01-03 Personalized production of biologics and method for reprogramming somatic cells

Publications (2)

Publication Number Publication Date
BR112013018744A2 true BR112013018744A2 (pt) 2016-09-20
BR112013018744B1 BR112013018744B1 (pt) 2022-03-29

Family

ID=45563510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018744-1A BR112013018744B1 (pt) 2011-01-03 2012-01-03 Método para produzir um polipetídeo ou uma proteína recombinante

Country Status (14)

Country Link
US (2) US9512200B2 (pt)
EP (1) EP2661491A1 (pt)
JP (2) JP6223829B2 (pt)
KR (2) KR20170120726A (pt)
CN (2) CN108017692A (pt)
AU (1) AU2012204501B2 (pt)
BR (1) BR112013018744B1 (pt)
IL (1) IL227299B (pt)
MX (1) MX348776B (pt)
MY (1) MY161859A (pt)
RU (1) RU2595390C2 (pt)
SG (1) SG191836A1 (pt)
WO (1) WO2012094321A1 (pt)
ZA (1) ZA201305849B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916339B1 (en) 2013-10-31 2014-12-23 Vivex Biomedical, Inc. Spinal cord tissue dehydrated and micronized
WO2016088243A1 (ja) * 2014-12-05 2016-06-09 株式会社ニコン 判定装置、観察システム、観察方法、そのプログラム、細胞の製造方法、および細胞
US9402869B1 (en) 2015-03-27 2016-08-02 Vivex Biomedical, Inc. Treated neural tissue composition
WO2016178914A1 (en) * 2015-05-01 2016-11-10 Cesca Therapeutics, Inc. Intramuscular adaminstration of autologous bone marrw for treatment
ES2917884T3 (es) * 2015-06-18 2022-07-12 Yeda Res & Dev Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos
WO2017205559A1 (en) * 2016-05-25 2017-11-30 The Johns Hopkins University Engineered anucleate cellular and extracellular vesicles as a novel biologics delivery platform
DE112017007307T5 (de) 2017-03-24 2019-12-24 Honda Motor Co., Ltd. Motorstartsteuerungsvorrichtung
US11981928B2 (en) 2017-10-03 2024-05-14 Sdf Biopharma Inc. Methods for reducing elevated glucose levels
MA54792A (fr) * 2018-03-09 2021-12-01 Avrobio Inc Compositions et méthodes pour le traitement de la maladie de parkinson
CN111269878B (zh) * 2020-01-19 2022-02-11 深圳市北科生物科技有限公司 一种人多能干细胞转化为扩展多能干细胞的专用培养基及其应用
CN112143697B (zh) * 2020-10-08 2021-08-06 宁波希诺赛生物科技有限公司 一种促进胚胎干细胞增殖和分化的方法
US20220154148A1 (en) * 2020-11-18 2022-05-19 Xingxin Wang Methods for engineering human pluripotent stem cells for diabetes therapy by co-transduction

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
CA2324350A1 (en) 1998-03-23 1999-09-30 Zymogenetics, Inc. Cardiac-derived stem cells
ATE275977T1 (de) 1998-04-13 2004-10-15 Massachusetts Inst Technology Kamm-polymere zur regelung der zelloberflächenwechselwirkung
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
US20040033217A1 (en) 2002-05-31 2004-02-19 Padmavathy Vanguri Intraperitoneal delivery of genetically engineered mesenchymal stem cells
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
FR2878860A1 (fr) * 2004-12-08 2006-06-09 Vivalis Sa Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2007081631A2 (en) * 2006-01-04 2007-07-19 Healtheuniverse, Inc. Method of producing insulin-secreting cells from adult stem cells via transfection
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
KR101564044B1 (ko) * 2007-10-31 2015-10-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵초기화 방법
WO2009091543A1 (en) * 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
US20090241206A1 (en) 2008-03-04 2009-09-24 University Of Iowa Research Foundation Methods for cloning ferrets and transgenic ferret models for diseases
WO2009151207A1 (ko) * 2008-06-13 2009-12-17 한쎌 주식회사 인간 간성장인자를 발현하는 중간엽 줄기세포, 그의 제조방법 및 그의 간질환 치료제로서의 용도
WO2010022194A2 (en) * 2008-08-20 2010-02-25 Virxsys Corporation Compositions and methods for generation of pluripotent stem cells
DK2389434T3 (en) * 2009-01-26 2015-09-28 Pasteuria Bioscience Inc Novel pasteuria strain
WO2010117464A1 (en) 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
JP2010268789A (ja) * 2009-04-24 2010-12-02 Kumamoto Univ 細胞医薬の製造方法

Also Published As

Publication number Publication date
RU2595390C2 (ru) 2016-08-27
US9512200B2 (en) 2016-12-06
AU2012204501A1 (en) 2013-08-22
JP6223829B2 (ja) 2017-11-01
KR20140037036A (ko) 2014-03-26
WO2012094321A1 (en) 2012-07-12
KR20170120726A (ko) 2017-10-31
RU2013136357A (ru) 2015-02-10
MX348776B (es) 2017-06-28
MX2013007633A (es) 2015-07-14
JP2018007660A (ja) 2018-01-18
US10030230B2 (en) 2018-07-24
SG191836A1 (en) 2013-08-30
ZA201305849B (en) 2014-10-29
WO2012094321A4 (en) 2012-09-20
AU2012204501B2 (en) 2016-05-19
IL227299B (en) 2020-06-30
IL227299A0 (en) 2013-09-30
US20170081641A1 (en) 2017-03-23
JP6373459B2 (ja) 2018-08-15
CN108017692A (zh) 2018-05-11
US20120171722A1 (en) 2012-07-05
BR112013018744B1 (pt) 2022-03-29
NZ613888A (en) 2015-07-31
CN103403152A (zh) 2013-11-20
EP2661491A1 (en) 2013-11-13
MY161859A (en) 2017-05-15
JP2014501118A (ja) 2014-01-20

Similar Documents

Publication Publication Date Title
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
MX2023001878A (es) Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t.
MX2021000210A (es) Metodos y productos para transfeccion de celulas.
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
EP2548950A3 (en) Reprogramming T cells and hematopoietic cells
MY172864A (en) Noninvasive detection of fetal genetic abnormality
MX354049B (es) Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados.
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
BR112014002027A8 (pt) Gene pesticida axmi279 e métodos para a sua utilização
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
BR112014001909A2 (pt) gene da toxina axmi270 e métodos para a sua utilização
BR112014018610A2 (pt) alfa-amilase
BR112013004700A2 (pt) método para prevenir ou tratar doenças ou distúrbios cardiovasculares
FR3044017B1 (fr) Procede de transfection transitoire pour la production retrovirale
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
MX2016005824A (es) Metodo de cultivo celular.
IN2012DN00852A (pt)
BR112017014433A2 (pt) proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica
MX2008013397A (es) Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/01/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2755 DE 24-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.